MONTREAL -- (MARKET WIRE) -- 04/24/07 -- TOPIGEN Pharmaceuticals Inc., a clinical stage biopharmaceutical company specializing in respiratory disorders, today announced that Paul K. Wotton, Ph.D., President and Chief Executive Officer, will present an update on the company's clinical programs at two upcoming conferences: BioFinance 2007 and the 2007 BIO International Convention.

At each of these conferences, Dr. Wotton plans to provide updates on TOPIGEN's lead product candidate programs, TPI ASM8 and TPI 1020. Last year, TOPIGEN announced that inhaled TPI ASM8 was the first drug of its kind to show pharmacological activity in the respiratory tract of patients with mild-to-moderate asthma. The study validated TOPIGEN's proprietary multi-targeted therapeutic approach, demonstrating the drug candidate works effectively in the respiratory tract of patients with asthma and its favorable safety profile in this patient population. As a result, TPI ASM8 is currently being evaluated in an expanded, Phase II study.

TPI 1020 is a corticosteroid-derivative that was in-licensed from NicOx S.A. (Eurolist: NICOX) and is part of an exciting new class of nitric oxide (NO)-donating therapies. TOPIGEN has recently conducted a dose escalating 21-day Phase II safety study in asthmatic smokers and Dr. Wotton will provide an update on this program, including the commencement of a proof-of-concept Phase II study in Chronic Obstructive Pulmonary Disease (COPD) patients later this year.

Dr. Wotton will also provide an update on the recently formed strategic collaboration with NOVAGALI Pharma and expanding the application of TOPIGEN's proprietary multi-targeted, RNA-targeting platform technology to the new therapeutic category of allergic ocular diseases.

Presentation Information

Dr. Wotton will present at BioFinance 2007 (April 24-26, 2007) on April 25th at 4:00 p.m. in the Trinity V presentation room at the Toronto Marriott Eaton Centre.

Dr. Wotton will also present at the BIO Business Forum during the 2007 BIO International Convention (May 6-9, 2007), on May 8th at 10:45 a.m. in room B at the Boston Convention and Exhibition Center in Boston, MA. TOPIGEN will also have a booth (#1020) at the Quebec-Canada Pavilion.

Dr. Wotton will be available for one-on-one meetings during both conferences.

About BioFinance 2007

BioFinance 2007 is the life science industry's leading investor conference in Canada. The meeting brings together key industry players to consider investment opportunities and issues affecting companies in biotechnology, medical devices, drug delivery, diagnostics, medical systems and research tools. Participants include senior life science executives, institutional and venture investors, industry analysts, corporate finance executives and experts from the medical communities in Canada, the U.S. and Europe. This year, the conference expects more than 100 company presentations. For more information about BioFinance 2007 please visit http://www.biofinance.ca/BioFinance.

About the 2007 BIO International Convention

The BIO International Convention is the largest global annual event for biotechnology, with a world-class program featuring renowned speakers, a value-packed exhibit and countless business opportunities. Over 20,000 industry leaders and over 1,800 exhibitors are expected to attend the conference this year. The BIO Business Forum at this meeting brings together thousands of biotech and pharmaceutical company executives, along with innovators and investors, to explore in-licensing and out-licensing opportunities and to initiate partnerships for growth. Nearly 300 biotech and pharmaceutical companies from around the world are expected to present this year, and representatives from over 1,500 companies will take part in what is considered to be the world's largest partnering program. For more information about the 2007 BIO International Convention or the BIO Business Forum please visit http://www.bio2007.org/

About TOPIGEN

TOPIGEN is a privately held, clinical-stage biopharmaceutical company focused on developing new classes of inhaled drugs for respiratory diseases such as asthma, COPD and allergic rhinitis. TOPIGEN's pipeline includes small molecule and RNA-targeting therapeutics. The Company has two lead product candidates, inhaled TPI ASM8 for the treatment of asthma and inhaled TPI 1020 for the treatment of Chronic Obstructive Pulmonary Disease (COPD). Both are currently undergoing Phase II trials. By topically targeting multiple affected airway receptors, the Company expects to improve outcomes for many patients with respiratory diseases. This specific approach has shown promising preclinical and clinical results in inhibiting the underlying inflammation associated with many pulmonary conditions.

Current venture investors include CDP Capital - Technology Ventures, Desjardins Venture Capital, T2C2 / BIO, Fonds de solidarité FTQ, BDC Venture Capital and Multiple Capital Inc. For more detailed information on TOPIGEN visit www.topigen.com.

Corporate Contact:
Paul K. Wotton
TOPIGEN Pharmaceuticals, Inc.
(514) 868-0404
Email Contact

IR/PR Contact:
Dory Valiquette
LaVoie Group
(978) 745-4200 X106
Email Contact